Professor Jan-Willem Alffenaar

A15 - Pharmacy And Bank Building
The University of Sydney

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Gafar, F., Arifin, H., Jurnalis, Y., Yani, F., Fitria, N., Alffenaar, J., Wilffert, B. (2019). Antituberculosis Drug-induced Liver Injury in Children: Incidence and Risk Factors During the Two-month Intensive Phase of Therapy. Pediatric Infectious Disease Journal, 38(1), 50-53. [More Information]
  • Daskapan, A., Tran, Q., Cattaneo, D., Gervasoni, C., Resnati, C., Stienstra, Y., Bierman, W., Kosterink, J., Van Der Werf, T., Alffenaar, J., et al (2019). Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data. Therapeutic Drug Monitoring, 41(1), 59-65. [More Information]
  • van Rijn, S., Zuur, M., Anthony, R., Wilffert, B., Van Altena, R., Akkerman, O., de Lange, W., Van Der Werf, T., Kosterink, J., Alffenaar, J. (2019). Evaluation of carbapenems for treatment of multi- and extensively drug-resistant mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 63(2), 1-13. [More Information]
  • Borisov, S., D�Ambrosio, L., Centis, R., Tiberi, S., Dheda, K., Alffenaar, J., Amale, R., Belilowski, E., Bruchfeld, J., et al (2019). Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery. Journal of Infection, 78(1), 35-39. [More Information]
  • Milliken, E., de Swart, A., Alffenaar, J., Marriott, D., Riezebos-Brilman, A., Schteinman, A., Evans, A., Glanville, A., Verschuuren, E., Reuter, S. (2019). Population pharmacokinetics of ribavirin in lung transplant recipients and examination of current and alternative dosing regimens. Journal of Antimicrobial Chemotherapy, 74(3), 691-698. [More Information]
  • Dekkers, B., Akkerman, O., Alffenaar, J. (2019). Role of therapeutic drug monitoring in treatment optimization in tuberculosis and diabetes mellitus comorbidity. Antimicrobial Agents and Chemotherapy, 63(2), 1-3. [More Information]
  • Sturkenboom, M., Simbar, N., Akkerman, O., Ghimire, S., Bolhuis, M., Alffenaar, J. (2018). Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment. Clinical Infectious Diseases, 67(Suppl 3), S303-S307. [More Information]
  • Pieterman, E., te Brake, L., de Knegt, G., van der Meijden, A., Alffenaar, J., Bax, H., Aarnoutse, R., de Steenwinkel, J. (2018). Assessment of the additional value of verapamil to a moxifloxacin and linezolid combination regimen in a murine tuberculosis model. Antimicrobial Agents and Chemotherapy, 62(9), 1-9. [More Information]
  • Van Anh Nguyen, T., Anthony, R., Banuls, A., Van Anh Nguyen, T., Vu, D., Alffenaar, J. (2018). Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention. Clinical Infectious Diseases, 66(10), 1625-1630. [More Information]
  • Zuur, M., Van Asselt, A., van 't Boveneind-Vrubleuskaya, N., Aleksa, A., Postma, M., Alffenaar, J. (2018). Cost-utility analysis of high-dose treatment for intermediatesusceptible, dose-dependent tuberculosis patients. International Journal of Tuberculosis and Lung Disease, 22(9), 991-999. [More Information]
  • Deshpande, D., Alffenaar, J., Koser, C., Dheda, K., Chapagain, M., Simbar, N., Schon, T., Sturkenboom, M., McIlleron, H., et al (2018). d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal. Clinical Infectious Diseases, 67(3), S308-S316. [More Information]
  • Koster, R., Greijdanus, B., Alffenaar, J., Touw, D. (2018). Dried blood spot analysis of creatinine with LC-MS/MS in addition to immunosuppressants analysis. Analytical and Bioanalytical Chemistry, 407(6), 1585-1594. [More Information]
  • Martial, L., Kerkhoff, J., Martinez, N., Rodriguez, M., Coronel, R., Molinas, G., Roman, M., Gomez, R., Aguirre, S., Jongedijk, E., et al (2018). Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children. International Journal of Antimicrobial Agents, 52(1), 109-113. [More Information]
  • Dijkstra, J., van der Laan, T., Akkerman, O., Bolhuis, M., de Lange, W., Kosterink, J., Van Der Werf, T., Alffenaar, J., van Soolingen, D. (2018). In vitro susceptibility of Mycobacterium tuberculosis to Amikacin, kanamycin, and capreomycin. Antimicrobial Agents and Chemotherapy, 62(3), 1-6. [More Information]
  • Zuur, M., Pasipanodya, J., van Soolingen, D., Van Der Werf, T., Gumbo, T., Alffenaar, J. (2018). Intermediate Susceptibility Dose-Dependent Breakpoints for High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs. Clinical Infectious Diseases, 67(11), 1750-1759. [More Information]
  • Dekkers, B., Veringa, A., Marriott, D., Boonstra, J., van�der�Elst, K., Doukas, F., McLachlan, A., Alffenaar, J. (2018). Invasive Candidiasis in the Elderly: Considerations for Drug Therapy. Drugs and Aging, 35(9), 781-789. [More Information]
  • Millard, J., Pertinez, H., Bonnett, L., Hodel, E., Dartois, V., Johnson, J., Caws, M., Tiberi, S., Bolhuis, M., Alffenaar, J., et al (2018). Linezolid pharmacokinetics in MDR-TB: A systematic review, meta-analysis and Monte Carlo simulation. Journal of Antimicrobial Chemotherapy, 73(7), 1755-1762. [More Information]
  • Bolhuis, M., Akkerman, O., Sturkenboom, M., Ghimire, S., Srivastava, S., Gumbo, T., Alffenaar, J. (2018). Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment. Clinical Infectious Diseases, 67(3), S327-S335. [More Information]
  • Cano-Muniz, S., Anthony, R., Niemann, S., Alffenaar, J. (2018). New approaches and therapeutic options for mycobacterium tuberculosis in a dormant state. Clinical Microbiology Reviews, 31(1), 1-13. [More Information]
  • Gumbo, T., Alffenaar, J. (2018). Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs. Clinical Infectious Diseases, 67(3), S267-S273. [More Information]
  • Stott, K., Pertinez, H., Sturkenboom, M., Boeree, M., Aarnoutse, R., Ramachandran, G., Requena-Mendez, A., Peloquin, C., Alffenaar, J., et al (2018). Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: A systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 73(9), 2305-2313. [More Information]
  • Forsman, L., Niward, K., Hu, Y., Zheng, R., Zheng, X., Ke, R., Cai, W., Hong, C., Alffenaar, J., et al (2018). Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study. BMJ Open, 8, 1-8. [More Information]
  • Perwitasari, D., Darmawan, E., Mulyani, U., Van Der Vlies, P., Alffenaar, J., Atthobar, J., Wilffert, B. (2018). Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in Indonesian tuberculosis patients. International Journal of Mycobacteriology, 7(4), 380-386. [More Information]
  • van den Elsen, S., Sturkenboom, M., van 't Boveneind-Vrubleuskaya, N., Skrahina, A., van Der Werf, T., Heysell, S., Mpagama, S., Migliori, G., Alffenaar, J., et al (2018). Population pharmacokinetic model and limited sampling strategies for personalized dosing of levofloxacin in tuberculosis patients. Antimicrobial Agents and Chemotherapy, 62(12), 1-10. [More Information]
  • Daskapan, A., Stienstra, Y., Kosterink, J., Bierman, W., Van Der Werf, T., Touw, D., Alffenaar, J. (2018). Risk factors contributing to a low darunavir plasma concentration. British Journal of Clinical Pharmacology, 84(3), 456-461. [More Information]
  • Pradipta, I., Forsman, L., Bruchfeld, J., Hak, E., Alffenaar, J. (2018). Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis. Journal of Infection, 77(6), 469-478. [More Information]
  • Boonstra, J., Jongedijk, E., Koster, R., Touw, D., Alffenaar, J. (2018). Simple and robust LC-MS/MS analysis method for therapeutic drug monitoring of micafungin. Bioanalysis, 10(11), 877-886. [More Information]
  • van den Elsen, S., Oostenbrink, L., Heysell, S., Hira, D., Touw, D., Akkerman, O., Bolhuis, M., Alffenaar, J. (2018). Systematic Review of Salivary Versus Blood Concentrations of Antituberculosis Drugs and Their Potential for Salivary Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 40(1), 17-37. [More Information]
  • Zhang, M., Wang, S., Wilffert, B., Tong, R., van Soolingen, D., van den Hof, S., Alffenaar, J. (2018). The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis. British Journal of Clinical Pharmacology, 84(12), 2747-2760. [More Information]
  • Ahmad, N., Ahuja, S., Akkerman, O., Alffenaar, J., Anderson, L., Baghaei, P., Bang, D., Barry, P., Bastos, M., Behera, D., Fox, G., et al (2018). Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. The Lancet, 392(10150), 821-834. [More Information]
  • Maryandyshev, A., Pontali, E., Tiberi, S., Akkerman, O., Ganatra, S., Sadutshang, T., Alffenaar, J., Amale, R., Mullerpattan, J., et al (2017). Bedaquiline and delamanid combination treatment of 5 patients with pulmonary extensively drug-resistant tuberculosis. Emerging Infectious Diseases, 23(10), 1718-1721. [More Information]
  • Veringa, A., Geling, S., Span, L., Vermeulen, K., Zijlstra, J., Van Der Werf, T., Kosterink, J., Alffenaar, J. (2017). Bioavailability of voriconazole in hospitalised patients. International Journal of Antimicrobial Agents, 49(2), 243-246. [More Information]
  • Veenhof, H., Koster, R., Alffenaar, J., Berger, S., Bakker, S., Touw, D. (2017). Clinical Validation of Simultaneous Analysis of Tacrolimus, Cyclosporine A, and Creatinine in Dried Blood Spots in Kidney Transplant Patients. Transplantation, 101(7), 1727-1733. [More Information]
  • Koster, R., Veenhof, H., Botma, R., Hoekstra, A., Berger, S., Bakker, S., Alffenaar, J., Touw, D. (2017). Dried blood spot validation of five immunosuppressants, without hematocrit correction, on two LC-MS/MS systems. Bioanalysis, 9(7), 553-563. [More Information]
  • Borisov, S., Dheda, K., Enwerem, M., Leyet, R., D�Ambrosio, L., Centis, R., Sotgiu, G., Tiberi, S., Alffenaar, J., Maryandyshev, A., et al (2017). Effectiveness and safety of bedaquilinecontaining regimens in the treatment of MDR- and XDR-TB: A multicentre study. European Respiratory Journal, 49(5), 1-12. [More Information]
  • Muilwijk, E., Dekkers, B., Henriet, S., Verweij, P., Witjes, B., Oude Lashof, A., Groeneveld, G., van der Hoeven, J., Alffenaar, J., Russel, F., et al (2017). Flucloxacillin results in suboptimal plasma voriconazole concentrations. Antimicrobial Agents and Chemotherapy, 61(9), 1-5. [More Information]
  • Daskapan, A., Dijkema, D., de Weerd, D., Bierman, W., Kosterink, J., Van Der Werf, T., Alffenaar, J., Stienstra, Y. (2017). Food intake and darunavir plasma concentrations in people living with HIV in an outpatient setting. British Journal of Clinical Pharmacology, 83(10), 2325-2329. [More Information]
  • Alffenaar, J., Akkerman, O., Anthony, R., Tiberi, S., Heysell, S., Grobusch, M., Cobelens, F., van Soolingen, D. (2017). Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers. Expert Review of Anti-Infective Therapy, 15(1), 11-21. [More Information]
  • van der Elst, K., Veringa, A., Zijlstra, J., Beishuizen, A., Klont, R., Brummelhuis-Visser, P., Uges, D., Touw, D., Kosterink, J., Van Der Werf, T., et al (2017). Low caspofungin exposure in patients in intensive care units. Antimicrobial Agents and Chemotherapy, 61(2), 1-10. [More Information]
  • van Rijn, S., Zuur, M., van Altena, R., Akkerman, O., Proost, J., de Lange, W., Kerstjens, H., Touw, D., Van Der Werf, T., Kosterink, J., et al (2017). Pharmacokinetic modeling and limited sampling strategies based on healthy volunteers for monitoring of ertapenem in patients with multidrug-resistant tuberculosis. Antimicrobial Agents and Chemotherapy, 61(4), 1-9. [More Information]
  • Boonstra, J., van der Elst, K., Veringa, A., Jongedijk, E., Bruggemann, R., Koster, R., Kampinga, G., Kosterink, J., van Derwerf, T., Zijlstra, J., et al (2017). Pharmacokinetic properties of micafungin in critically ill patients diagnosed with invasive candidiasis. Antimicrobial Agents and Chemotherapy, 61(12), 1-11. [More Information]
  • van 't Boveneind-Vrubleuskaya, N., Seuruk, T., van Hateren, K., van der Laan, T., Kosterink, J., Van Der Werf, T., van Soolingen, D., van den Hof, S., Skrahina, A., Alffenaar, J. (2017). Pharmacokinetics of levofloxacin in multidrug- and extensively drug-resistant tuberculosis patients. Antimicrobial Agents and Chemotherapy, 61(8), 1-10. [More Information]
  • Van Altena, R., Dijkstra, J., van der Meer, M., Borjas-Howard, J., Kosterink, J., van Soolingen, D., van Derwerf, T., Alffenaar, J. (2017). Reduced chance of hearing loss associated with therapeutic drug monitoring of aminoglycosides in the treatment of multidrug-resistant tuberculosis. Antimicrobial Agents and Chemotherapy, 61(3), 1-10. [More Information]
  • Kamp, J., Bolhuis, M., Tiberi, S., Akkerman, O., Centis, R., de Lange, W., Kosterink, J., Van Der Werf, T., Migliori, G., Alffenaar, J. (2017). Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis. International Journal of Antimicrobial Agents, 49(6), 688-694. [More Information]
  • van Rijn, S., Srivastava, S., Wessels, M., van Soolingen, D., Alffenaar, J., Gumbo, T. (2017). Sterilizing effect of ertapenem-clavulanate in a hollow-fiber model of tuberculosis and implications on clinical dosing. Antimicrobial Agents and Chemotherapy, 61(9), 1-10. [More Information]
  • Aardema, H., Nannan Panday, P., Wessels, M., van Hateren, K., Dieperink, W., Kosterink, J., Alffenaar, J., Zijlstra, J. (2017). Target attainment with continuous dosing of piperacillin/tazobactam in critical illness: a prospective observational study. International Journal of Antimicrobial Agents, 50(1), 68-73. [More Information]
  • Alffenaar, J., van Ingen, J. (2017). Treatment of Mycobacterium avium-intracellulare complex: A great leap forward. Journal of Antimicrobial Chemotherapy, 72, ii1-ii2. [More Information]
  • Kuiken, N., Rings, E., Alffenaar, J., Havinga, R., Jurdzinski, A., Groen, A., Tissing, W. (2017). Tumor Necrosis Factor-Alpha Inhibitor Etanercept Does Not Alter Methotrexate-Induced Gastrointestinal Mucositis in Rats. Journal of Pediatric Gastroenterology and Nutrition, 65(2), e28-e34. [More Information]
  • Veringa, A., ter Avest, M., Span, L., van den Heuvel, E., Touw, D., Zijlstra, J., Kosterink, J., Van Der Werf, T., Alffenaar, J. (2017). Voriconazole metabolism is influenced by severe inflammation: A prospective study. Journal of Antimicrobial Chemotherapy, 72(1), 261-267. [More Information]
  • Nguyen, T., Cao, T., Akkerman, O., Tiberi, S., Vu, D., Alffenaar, J. (2016). Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis. Expert Review of Clinical Pharmacology, 9(8), 1025-1037. [More Information]
  • Tiberi, S., Sotgiu, G., D�Ambrosio, L., Centis, R., Arbex, M., Arrascue, E., Alffenaar, J., Caminero, J., Gaga, M., et al (2016). Comparison of effectiveness and safety of imipenem/clavulanate-versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. European Respiratory Journal, 47(6), 1758-1766. [More Information]
  • Zuur, M., Bolhuis, M., Anthony, R., den Hertog, A., van der Laan, T., Wilffert, B., de Lange, W., van Soolingen, D., Alffenaar, J. (2016). Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis. Expert Opinion on Drug Metabolism and Toxicology, 12(5), 509-521. [More Information]
  • Cattaneo, D., Alffenaar, J., Neely, M. (2016). Drug monitoring and individual dose optimization of antimicrobial drugs: Oxazolidinones. Expert Opinion on Drug Metabolism and Toxicology, 12(5), 533-544. [More Information]
  • Tiberi, S., Payen, M., Sotgiu, G., D�Ambrosio, L., Guizado, V., Alffenaar, J., Arbex, M., Caminero, J., Centis, R., de Lorenzo, S., et al (2016). Effectiveness and safety of meropenem/ clavulanate-containing regimens in the treatment of MDR- and XDR-TB. European Respiratory Journal, 47(4), 1235-1243. [More Information]
  • Hofman, S., Segers, M., Ghimire, S., Bolhuis, M., Sturkenboom, M., van Soolingen, D., Alffenaar, J. (2016). Emerging drugs and alternative possibilities in the treatment of tuberculosis. Expert Opinion on Emerging Drugs, 21(1), 103-116. [More Information]
  • Dijkstra, J., Voerman, A., Greijdanus, B., Touw, D., Alffenaar, J. (2016). Immunoassay analysis of kanamycin in serum using the tobramycin kit. Antimicrobial Agents and Chemotherapy, 60(8), 4646-4651. [More Information]
  • Saktiawati, A., Sturkenboom, M., Stienstra, Y., Subronto, Y., Sumardi, S., Kosterink, J., Van Der Werf, T., Alffenaar, J. (2016). Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: A randomized cross-over trial. Journal of Antimicrobial Chemotherapy, 71(3), 703-710. [More Information]
  • Veringa, A., Sturkenboom, M., Dekkers, B., Koster, R., Roberts, J., Peloquin, C., Touw, D., Alffenaar, J. (2016). LC-MS/MS for Therapeutic Drug Monitoring of anti-infective drugs. Trends In Analytical Chemistry, 84, 34-40. [More Information]
  • Ventura, M., van Wanrooy, M., Span, L., Rodgers, M., van den Heuvel, E., Uges, D., Van Der Werf, T., Kosterink, J., Alffenaar, J. (2016). Longitudinal analysis of the effect of inflammation on voriconazole trough concentrations. Antimicrobial Agents and Chemotherapy, 60(5), 2727-2731. [More Information]
  • Huurneman, L., Neely, M., Veringa, A., Perez, F., Ramos-Martin, V., Tissing, W., Alffenaar, J., Hope, W. (2016). Pharmacodynamics of voriconazole in children: Further steps along the path to true individualized therapy. Antimicrobial Agents and Chemotherapy, 60(4), 2336-2342. [More Information]
  • Alsaad, N., Dijkstra, J., Akkerman, O., de Lange, W., van Soolingen, D., Kosterink, J., Van Der Werf, T., Alffenaar, J. (2016). Pharmacokinetic evaluation of sulfamethoxazole at 800 milligrams once daily in the treatment of tuberculosis. Antimicrobial Agents and Chemotherapy, 60(7), 3942-3947. [More Information]
  • Ghimire, S., van 't Boveneind-Vrubleuskaya, N., Akkerman, O., de Lange, W., van Soolingen, D., Kosterink, J., Van Der Werf, T., Wilffert, B., Touw, D., Alffenaar, J. (2016). Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB. Journal of Antimicrobial Chemotherapy, 71(10), 2691-2703. [More Information]
  • van Rijn, S., Van Altena, R., Akkerman, O., van Soolingen, D., van der Laan, T., De Lange, W., Kosterink, J., Van Der Werf, T., Alffenaar, J. (2016). Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis. European Respiratory Journal, 47(4), 1229-1234. [More Information]
  • van 't Boveneind-Vrubleuskaya, N., Daskapan, A., Kosterink, J., van Der Werf, T., van den Hof, S., Alffenaar, J. (2016). Predictors of Prolonged TB Treatment in a Dutch Outpatient Setting. PloS One, 11(11), 1-12. [More Information]
  • Srivastava, S., van Rijn, S., Wessels, A., Alffenaar, J., Gumbo, T. (2016). Susceptibility testing of antibiotics that degrade faster than the doubling time of slow-growing mycobacteria: Ertapenem sterilizing effect versus Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 60(5), 3193-3195. [More Information]
  • Dekkers, B., Bakker, M., van der Elst, K., Sturkenboom, M., Veringa, A., Span, L., Alffenaar, J. (2016). Therapeutic Drug Monitoring of Posaconazole: an Update. Current Fungal Infection Reports, 10(2), 51-61. [More Information]
  • Hoppentocht, M., Akkerman, O., Hagedoorn, P., Alffenaar, J., Van Der Werf, T., Kerstjens, H., Frijlink, H., De Boer, A. (2016). Tolerability and pharmacokinetic evaluation of inhaled dry powder tobramycin free base in non-cystic fibrosis bronchiectasis patients. PloS One, 11(3), 1-12. [More Information]
  • van Wanrooy, M., Rodgers, M., Span, L., Zijlstra, J., Uges, D., Kosterink, J., Van Der Werf, T., Alffenaar, J. (2016). Voriconazole therapeutic drug monitoring practices in intensive care. Therapeutic Drug Monitoring, 38(3), 313-318. [More Information]
  • Alffenaar, J., Bolhuis, M., van Hateren, K., Sturkenboom, M., Akkerman, O., De Lange, W., Greijdanus, B., Van Der Werf, T., Touw, D. (2015). Determination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometry. Antimicrobial Agents and Chemotherapy, 59(9), 5675-5680. [More Information]
  • van der Paardt, A., Wilffert, B., Akkerman, O., De Lange, W., van Soolingen, D., Sinha, B., Van Der Werf, T., Kosterink, J., Alffenaar, J. (2015). Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis. European Respiratory Journal, 46(2), 444-455. [More Information]
  • Dijkstra, J., Van Altena, R., Akkerman, O., de Lange, W., Proost, J., Van Der Werf, T., Kosterink, J., Alffenaar, J. (2015). Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis. International Journal of Antimicrobial Agents, 46(3), 332-337. [More Information]
  • van Wanrooy, M., Proost, J., Rodgers, M., Zijlstra, J., Uges, D., Kosterink, J., Van Der Werf, T., Alffenaar, J. (2015). Limited-sampling strategies for anidulafungin in critically ill patients. Antimicrobial Agents and Chemotherapy, 59(2), 1177-1181. [More Information]
  • Sturkenboom, M., Mulder, L., de Jager, A., Van Altena, R., Aarnoutse, R., De Lange, W., Proost, J., Kosterink, J., Van Der Werf, T., Alffenaar, J. (2015). Pharmacokinetic modeling and optimal sampling strategies for therapeutic drug monitoring of rifampin in patients with tuberculosis. Antimicrobial Agents and Chemotherapy, 59(8), 4907-4913. [More Information]
  • Dijkstra, J., Alsaad, N., van Hateren, K., Greijdanus, B., Touw, D., Alffenaar, J. (2015). Quantification of co-trimoxazole in serum and plasma using MS/MS. Bioanalysis, 7(21), 2741-2749. [More Information]
  • Hofman, S., Bolhuis, M., Koster, R., Akkerman, O., van Assen, S., Stove, C., Alffenaar, J. (2015). Role of therapeutic drug monitoring in pulmonary infections: Use and potential for expanded use of dried blood spot samples. Bioanalysis, 7(4), 481-495. [More Information]
  • van der Elst, K., Brouwers, C., van den Heuvel, E., van Wanrooy, M., Uges, D., Van Der Werf, T., Kosterink, J., Span, L., Alffenaar, J. (2015). Subtherapeutic posaconazole exposure and treatment outcome in patients with invasive fungal disease. Therapeutic Drug Monitoring, 37(6), 766-771. [More Information]
  • Koster, R., Botma, R., Greijdanus, B., Uges, D., Kosterink, J., Touw, D., Alffenaar, J. (2015). The performance of five different dried blood spot cards for the analysis of six immunosuppressants. Bioanalysis, 7(10), 1225-1235. [More Information]
  • Koster, R., Alffenaar, J., Botma, R., Greijdanus, B., Uges, D., Kosterink, J., Touw, D. (2015). The relation of the number of hydrogen-bond acceptors with recoveries of immunosuppressants in DBS analysis. Bioanalysis, 7(14), 1717-1722. [More Information]
  • Sotgiu, G., Alffenaar, J., Centis, R., D�Ambrosio, L., Spanevello, A., Piana, A., Migliori, G. (2015). Therapeutic drug monitoring: How to improve drug dosage and patient safety in tuberculosis treatment. International Journal of Infectious Diseases, 32, 101-104. [More Information]
  • Koster, R., Alffenaar, J., Botma, R., Greijdanus, B., Touw, D., Uges, D., Kosterink, J. (2015). What is the right blood hematocrit preparation procedure for standards and quality control samples for dried blood spot analysis? Bioanalysis, 7(3), 345-351. [More Information]
  • Koster, R., Alffenaar, J., Greijdanus, B., VanDerNagel, J., Uges, D. (2014). Application of sweat patch screening for 16 drugs and metabolites using a fast and highly selective LC-MS/MS method. Therapeutic Drug Monitoring, 36(1), 35-45. [More Information]
  • Koster, R., Alffenaar, J., Greijdanus, B., VanDerNagel, J., Uges, D. (2014). Fast and highly selective LC-MS/MS screening for THC and 16 other abused drugs and metabolites in human hair to monitor patients for drug abuse. Therapeutic Drug Monitoring, 36(2), 234-243. [More Information]
  • Lempers, V., Alffenaar, J., Touw, D., Burger, D., Uges, D., Aarnoutse, R., Bruggemann, R. (2014). Five year results of an international proficiency testing programme for measurement of antifungal drug concentrations. Journal of Antimicrobial Chemotherapy, 69(11), 2988-2994. [More Information]
  • van der Elst, K., Pereboom, M., van den Heuvel, E., Kosterink, J., Scholvinck, E., Alffenaar, J. (2014). Insufficient fluconazole exposure in pediatric cancer patients and the need for therapeutic drug monitoring in critically Ill children. Clinical Infectious Diseases, 59(11), 1527-1533. [More Information]
  • Lange, C., Abubakar, I., Alffenaar, J., Bothamley, G., Caminero, J., Carvalho, A., Chang, K., Codecasa, L., Correia, A., et al (2014). Management of patients with multidrugresistant/ extensively drug-resistant tuberculosis in Europe: A TBNET consensus statement. European Respiratory Journal, 44(1), 23-63. [More Information]
  • Dalboge, C., Nielsen, X., Dalhoff, K., Alffenaar, J., Duno, M., Buchard, A., Uges, D., Jensen, A., Jurgens, G., et al (2014). Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis. Journal of Cystic Fibrosis, 13(2), 179-185. [More Information]
  • Magis-Escurra, C., Later-Nijland, H., Alffenaar, J., Broeders, J., Burger, D., Van Crevel, R., Boeree, M., Donders, A., van Altena, R., van Der Werf, T., et al (2014). Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin. International Journal of Antimicrobial Agents, 44(3), 229-234. [More Information]
  • Alsaad, N., Wilffert, B., Van Altena, R., de Lange, W., Van Der Werf, T., Kosterink, J., Alffenaar, J. (2014). Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis. European Respiratory Journal, 43(3), 884-897. [More Information]
  • van Rijn, S., Wessels, A., Greijdanus, B., Touw, D., Alffenaar, J. (2014). Quantification and validation of ertapenem using a liquid chromatography-tandem mass spectrometry method. Antimicrobial Agents and Chemotherapy, 58(6), 3481-3484. [More Information]
  • Dijkstra, J., Sturkenboom, M., van Hateren, K., Koster, R., Greijdanus, B., Alffenaar, J. (2014). Quantification of amikacin and kanamycin in serum using a simple and validated LC-MS/MS method. Bioanalysis, 6(16), 2125-2133. [More Information]
  • Vu, D., Koster, R., Bolhuis, M., Greijdanus, B., Van Altena, R., Nguyen, D., Brouwers, J., Uges, D., Alffenaar, J. (2014). Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC-MS/MS. Talanta, 121, 9-17. [More Information]
  • Bolhuis, M., Van Altena, R., van Soolingen, D., De Lange, W., Uges, D., Van Der Werf, T., Kosterink, J., Alffenaar, J. (2013). Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. European Respiratory Journal, 42(6), 1614-1621. [More Information]
  • Bolhuis, M., van Altena, R., van Hateren, K., De Lange, W., Greijdanus, B., Uges, D., Kosterink, J., Van Der Werf, T., Alffenaar, J. (2013). Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis. Antimicrobial Agents and Chemotherapy, 57(8), 3676-3680. [More Information]
  • van der Elst, K., Span, L., van Hateren, K., Vermeulen, K., Van Der Werf, T., Greijdanus, B., Kosterink, J., Uges, D., Alffenaar, J. (2013). Dried blood spot analysis suitable for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole. Antimicrobial Agents and Chemotherapy, 57(10), 4999-5004. [More Information]
  • de Lorenzo, S., Alffenaar, J., Sotgiu, G., Centis, R., D�Ambrosio, L., Tiberi, S., Bolhuis, M., Van Altena, R., Viggiani, P., Piana, A., et al (2013). Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. European Respiratory Journal, 41(6), 1386-1392. [More Information]
  • Alsaad, N., Van Altena, R., Pranger, A., van Soolingen, D., De Lange, W., Kosterink, J., Alffenaar, J. (2013). Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis. European Respiratory Journal, 42(2), 504-512. [More Information]
  • Koster, R., Alffenaar, J., Greijdanus, B., Uges, D. (2013). Fast LC-MS/MS analysis of tacrolimus, sirolimus, everolimus and cyclosporin A in dried blood spots and the influence of the hematocrit and immunosuppressant concentration on recovery. Talanta, 115, 47-54. [More Information]
  • Magis-Escurra, C., Alffenaar, J., Hoefnagels, I., Dekhuijzen, P., Boeree, M., van Ingen, J., Aarnoutse, R. (2013). Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections. International Journal of Antimicrobial Agents, 42(3), 256-261. [More Information]
  • van Wanrooy, M., Santoe, R., van der Elst, K., Wilmer, C., van Hateren, K., Wessels, A., Greijdanus, B., Alffenaar, J., Uges, D. (2013). Simultaneous Quantification of Anidulafungin and Caspofungin in Plasma by an Accurate and Simple Liquid Chromatography Tandem Mass-Spectrometric Method. Therapeutic Drug Monitoring, 35(6), 778-784. [More Information]
  • Vu, D., Koster, R., Wessels, A., Greijdanus, B., Alffenaar, J., Uges, D. (2013). Troubleshooting carry-over of LC-MS/MS method for rifampicin, clarithromycin and metabolites in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 917-918, 1-4. [More Information]
  • van der Lijke, H., Alffenaar, J., Kok, W., Greijdanus, B., Uges, D. (2012). Determination of ribavirin in human serum using liquid chromatography tandem mass spectrometry. Talanta, 88, 385-390. [More Information]
  • Vu, D., Bolhuis, M., Koster, R., Greijdanus, B., De Lange, W., Van Altena, R., Brouwers, J., Uges, D., Alffenaar, J. (2012). Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Antimicrobial Agents and Chemotherapy, 56(11), 5758-5763. [More Information]
  • Sotgiu, G., Centis, R., D�Ambrosio, L., Alffenaar, J., Anger, H., Caminero, J., Castiglia, P., de Lorenzo, S., Ferrara, G., Koh, W., et al (2012). Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: Systematic review and meta-analysis. European Respiratory Journal, 40(6), 1430-1442. [More Information]
  • van der Elst, K., Bruggemann, R., Rodgers, M., Alffenaar, J. (2012). Plasma concentrations of caspofungin at two different dosage regimens in a patient with hepatic dysfunction. Transplant Infectious Disease, 14(4), 440-443. [More Information]

2019

  • Gafar, F., Arifin, H., Jurnalis, Y., Yani, F., Fitria, N., Alffenaar, J., Wilffert, B. (2019). Antituberculosis Drug-induced Liver Injury in Children: Incidence and Risk Factors During the Two-month Intensive Phase of Therapy. Pediatric Infectious Disease Journal, 38(1), 50-53. [More Information]
  • Daskapan, A., Tran, Q., Cattaneo, D., Gervasoni, C., Resnati, C., Stienstra, Y., Bierman, W., Kosterink, J., Van Der Werf, T., Alffenaar, J., et al (2019). Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data. Therapeutic Drug Monitoring, 41(1), 59-65. [More Information]
  • van Rijn, S., Zuur, M., Anthony, R., Wilffert, B., Van Altena, R., Akkerman, O., de Lange, W., Van Der Werf, T., Kosterink, J., Alffenaar, J. (2019). Evaluation of carbapenems for treatment of multi- and extensively drug-resistant mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 63(2), 1-13. [More Information]
  • Borisov, S., D�Ambrosio, L., Centis, R., Tiberi, S., Dheda, K., Alffenaar, J., Amale, R., Belilowski, E., Bruchfeld, J., et al (2019). Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery. Journal of Infection, 78(1), 35-39. [More Information]
  • Milliken, E., de Swart, A., Alffenaar, J., Marriott, D., Riezebos-Brilman, A., Schteinman, A., Evans, A., Glanville, A., Verschuuren, E., Reuter, S. (2019). Population pharmacokinetics of ribavirin in lung transplant recipients and examination of current and alternative dosing regimens. Journal of Antimicrobial Chemotherapy, 74(3), 691-698. [More Information]
  • Dekkers, B., Akkerman, O., Alffenaar, J. (2019). Role of therapeutic drug monitoring in treatment optimization in tuberculosis and diabetes mellitus comorbidity. Antimicrobial Agents and Chemotherapy, 63(2), 1-3. [More Information]

2018

  • Sturkenboom, M., Simbar, N., Akkerman, O., Ghimire, S., Bolhuis, M., Alffenaar, J. (2018). Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment. Clinical Infectious Diseases, 67(Suppl 3), S303-S307. [More Information]
  • Pieterman, E., te Brake, L., de Knegt, G., van der Meijden, A., Alffenaar, J., Bax, H., Aarnoutse, R., de Steenwinkel, J. (2018). Assessment of the additional value of verapamil to a moxifloxacin and linezolid combination regimen in a murine tuberculosis model. Antimicrobial Agents and Chemotherapy, 62(9), 1-9. [More Information]
  • Van Anh Nguyen, T., Anthony, R., Banuls, A., Van Anh Nguyen, T., Vu, D., Alffenaar, J. (2018). Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention. Clinical Infectious Diseases, 66(10), 1625-1630. [More Information]
  • Zuur, M., Van Asselt, A., van 't Boveneind-Vrubleuskaya, N., Aleksa, A., Postma, M., Alffenaar, J. (2018). Cost-utility analysis of high-dose treatment for intermediatesusceptible, dose-dependent tuberculosis patients. International Journal of Tuberculosis and Lung Disease, 22(9), 991-999. [More Information]
  • Deshpande, D., Alffenaar, J., Koser, C., Dheda, K., Chapagain, M., Simbar, N., Schon, T., Sturkenboom, M., McIlleron, H., et al (2018). d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal. Clinical Infectious Diseases, 67(3), S308-S316. [More Information]
  • Koster, R., Greijdanus, B., Alffenaar, J., Touw, D. (2018). Dried blood spot analysis of creatinine with LC-MS/MS in addition to immunosuppressants analysis. Analytical and Bioanalytical Chemistry, 407(6), 1585-1594. [More Information]
  • Martial, L., Kerkhoff, J., Martinez, N., Rodriguez, M., Coronel, R., Molinas, G., Roman, M., Gomez, R., Aguirre, S., Jongedijk, E., et al (2018). Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children. International Journal of Antimicrobial Agents, 52(1), 109-113. [More Information]
  • Dijkstra, J., van der Laan, T., Akkerman, O., Bolhuis, M., de Lange, W., Kosterink, J., Van Der Werf, T., Alffenaar, J., van Soolingen, D. (2018). In vitro susceptibility of Mycobacterium tuberculosis to Amikacin, kanamycin, and capreomycin. Antimicrobial Agents and Chemotherapy, 62(3), 1-6. [More Information]
  • Zuur, M., Pasipanodya, J., van Soolingen, D., Van Der Werf, T., Gumbo, T., Alffenaar, J. (2018). Intermediate Susceptibility Dose-Dependent Breakpoints for High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs. Clinical Infectious Diseases, 67(11), 1750-1759. [More Information]
  • Dekkers, B., Veringa, A., Marriott, D., Boonstra, J., van�der�Elst, K., Doukas, F., McLachlan, A., Alffenaar, J. (2018). Invasive Candidiasis in the Elderly: Considerations for Drug Therapy. Drugs and Aging, 35(9), 781-789. [More Information]
  • Millard, J., Pertinez, H., Bonnett, L., Hodel, E., Dartois, V., Johnson, J., Caws, M., Tiberi, S., Bolhuis, M., Alffenaar, J., et al (2018). Linezolid pharmacokinetics in MDR-TB: A systematic review, meta-analysis and Monte Carlo simulation. Journal of Antimicrobial Chemotherapy, 73(7), 1755-1762. [More Information]
  • Bolhuis, M., Akkerman, O., Sturkenboom, M., Ghimire, S., Srivastava, S., Gumbo, T., Alffenaar, J. (2018). Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment. Clinical Infectious Diseases, 67(3), S327-S335. [More Information]
  • Cano-Muniz, S., Anthony, R., Niemann, S., Alffenaar, J. (2018). New approaches and therapeutic options for mycobacterium tuberculosis in a dormant state. Clinical Microbiology Reviews, 31(1), 1-13. [More Information]
  • Gumbo, T., Alffenaar, J. (2018). Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs. Clinical Infectious Diseases, 67(3), S267-S273. [More Information]
  • Stott, K., Pertinez, H., Sturkenboom, M., Boeree, M., Aarnoutse, R., Ramachandran, G., Requena-Mendez, A., Peloquin, C., Alffenaar, J., et al (2018). Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: A systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 73(9), 2305-2313. [More Information]
  • Forsman, L., Niward, K., Hu, Y., Zheng, R., Zheng, X., Ke, R., Cai, W., Hong, C., Alffenaar, J., et al (2018). Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study. BMJ Open, 8, 1-8. [More Information]
  • Perwitasari, D., Darmawan, E., Mulyani, U., Van Der Vlies, P., Alffenaar, J., Atthobar, J., Wilffert, B. (2018). Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in Indonesian tuberculosis patients. International Journal of Mycobacteriology, 7(4), 380-386. [More Information]
  • van den Elsen, S., Sturkenboom, M., van 't Boveneind-Vrubleuskaya, N., Skrahina, A., van Der Werf, T., Heysell, S., Mpagama, S., Migliori, G., Alffenaar, J., et al (2018). Population pharmacokinetic model and limited sampling strategies for personalized dosing of levofloxacin in tuberculosis patients. Antimicrobial Agents and Chemotherapy, 62(12), 1-10. [More Information]
  • Daskapan, A., Stienstra, Y., Kosterink, J., Bierman, W., Van Der Werf, T., Touw, D., Alffenaar, J. (2018). Risk factors contributing to a low darunavir plasma concentration. British Journal of Clinical Pharmacology, 84(3), 456-461. [More Information]
  • Pradipta, I., Forsman, L., Bruchfeld, J., Hak, E., Alffenaar, J. (2018). Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis. Journal of Infection, 77(6), 469-478. [More Information]
  • Boonstra, J., Jongedijk, E., Koster, R., Touw, D., Alffenaar, J. (2018). Simple and robust LC-MS/MS analysis method for therapeutic drug monitoring of micafungin. Bioanalysis, 10(11), 877-886. [More Information]
  • van den Elsen, S., Oostenbrink, L., Heysell, S., Hira, D., Touw, D., Akkerman, O., Bolhuis, M., Alffenaar, J. (2018). Systematic Review of Salivary Versus Blood Concentrations of Antituberculosis Drugs and Their Potential for Salivary Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 40(1), 17-37. [More Information]
  • Zhang, M., Wang, S., Wilffert, B., Tong, R., van Soolingen, D., van den Hof, S., Alffenaar, J. (2018). The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis. British Journal of Clinical Pharmacology, 84(12), 2747-2760. [More Information]
  • Ahmad, N., Ahuja, S., Akkerman, O., Alffenaar, J., Anderson, L., Baghaei, P., Bang, D., Barry, P., Bastos, M., Behera, D., Fox, G., et al (2018). Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. The Lancet, 392(10150), 821-834. [More Information]

2017

  • Maryandyshev, A., Pontali, E., Tiberi, S., Akkerman, O., Ganatra, S., Sadutshang, T., Alffenaar, J., Amale, R., Mullerpattan, J., et al (2017). Bedaquiline and delamanid combination treatment of 5 patients with pulmonary extensively drug-resistant tuberculosis. Emerging Infectious Diseases, 23(10), 1718-1721. [More Information]
  • Veringa, A., Geling, S., Span, L., Vermeulen, K., Zijlstra, J., Van Der Werf, T., Kosterink, J., Alffenaar, J. (2017). Bioavailability of voriconazole in hospitalised patients. International Journal of Antimicrobial Agents, 49(2), 243-246. [More Information]
  • Veenhof, H., Koster, R., Alffenaar, J., Berger, S., Bakker, S., Touw, D. (2017). Clinical Validation of Simultaneous Analysis of Tacrolimus, Cyclosporine A, and Creatinine in Dried Blood Spots in Kidney Transplant Patients. Transplantation, 101(7), 1727-1733. [More Information]
  • Koster, R., Veenhof, H., Botma, R., Hoekstra, A., Berger, S., Bakker, S., Alffenaar, J., Touw, D. (2017). Dried blood spot validation of five immunosuppressants, without hematocrit correction, on two LC-MS/MS systems. Bioanalysis, 9(7), 553-563. [More Information]
  • Borisov, S., Dheda, K., Enwerem, M., Leyet, R., D�Ambrosio, L., Centis, R., Sotgiu, G., Tiberi, S., Alffenaar, J., Maryandyshev, A., et al (2017). Effectiveness and safety of bedaquilinecontaining regimens in the treatment of MDR- and XDR-TB: A multicentre study. European Respiratory Journal, 49(5), 1-12. [More Information]
  • Muilwijk, E., Dekkers, B., Henriet, S., Verweij, P., Witjes, B., Oude Lashof, A., Groeneveld, G., van der Hoeven, J., Alffenaar, J., Russel, F., et al (2017). Flucloxacillin results in suboptimal plasma voriconazole concentrations. Antimicrobial Agents and Chemotherapy, 61(9), 1-5. [More Information]
  • Daskapan, A., Dijkema, D., de Weerd, D., Bierman, W., Kosterink, J., Van Der Werf, T., Alffenaar, J., Stienstra, Y. (2017). Food intake and darunavir plasma concentrations in people living with HIV in an outpatient setting. British Journal of Clinical Pharmacology, 83(10), 2325-2329. [More Information]
  • Alffenaar, J., Akkerman, O., Anthony, R., Tiberi, S., Heysell, S., Grobusch, M., Cobelens, F., van Soolingen, D. (2017). Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers. Expert Review of Anti-Infective Therapy, 15(1), 11-21. [More Information]
  • van der Elst, K., Veringa, A., Zijlstra, J., Beishuizen, A., Klont, R., Brummelhuis-Visser, P., Uges, D., Touw, D., Kosterink, J., Van Der Werf, T., et al (2017). Low caspofungin exposure in patients in intensive care units. Antimicrobial Agents and Chemotherapy, 61(2), 1-10. [More Information]
  • van Rijn, S., Zuur, M., van Altena, R., Akkerman, O., Proost, J., de Lange, W., Kerstjens, H., Touw, D., Van Der Werf, T., Kosterink, J., et al (2017). Pharmacokinetic modeling and limited sampling strategies based on healthy volunteers for monitoring of ertapenem in patients with multidrug-resistant tuberculosis. Antimicrobial Agents and Chemotherapy, 61(4), 1-9. [More Information]
  • Boonstra, J., van der Elst, K., Veringa, A., Jongedijk, E., Bruggemann, R., Koster, R., Kampinga, G., Kosterink, J., van Derwerf, T., Zijlstra, J., et al (2017). Pharmacokinetic properties of micafungin in critically ill patients diagnosed with invasive candidiasis. Antimicrobial Agents and Chemotherapy, 61(12), 1-11. [More Information]
  • van 't Boveneind-Vrubleuskaya, N., Seuruk, T., van Hateren, K., van der Laan, T., Kosterink, J., Van Der Werf, T., van Soolingen, D., van den Hof, S., Skrahina, A., Alffenaar, J. (2017). Pharmacokinetics of levofloxacin in multidrug- and extensively drug-resistant tuberculosis patients. Antimicrobial Agents and Chemotherapy, 61(8), 1-10. [More Information]
  • Van Altena, R., Dijkstra, J., van der Meer, M., Borjas-Howard, J., Kosterink, J., van Soolingen, D., van Derwerf, T., Alffenaar, J. (2017). Reduced chance of hearing loss associated with therapeutic drug monitoring of aminoglycosides in the treatment of multidrug-resistant tuberculosis. Antimicrobial Agents and Chemotherapy, 61(3), 1-10. [More Information]
  • Kamp, J., Bolhuis, M., Tiberi, S., Akkerman, O., Centis, R., de Lange, W., Kosterink, J., Van Der Werf, T., Migliori, G., Alffenaar, J. (2017). Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis. International Journal of Antimicrobial Agents, 49(6), 688-694. [More Information]
  • van Rijn, S., Srivastava, S., Wessels, M., van Soolingen, D., Alffenaar, J., Gumbo, T. (2017). Sterilizing effect of ertapenem-clavulanate in a hollow-fiber model of tuberculosis and implications on clinical dosing. Antimicrobial Agents and Chemotherapy, 61(9), 1-10. [More Information]
  • Aardema, H., Nannan Panday, P., Wessels, M., van Hateren, K., Dieperink, W., Kosterink, J., Alffenaar, J., Zijlstra, J. (2017). Target attainment with continuous dosing of piperacillin/tazobactam in critical illness: a prospective observational study. International Journal of Antimicrobial Agents, 50(1), 68-73. [More Information]
  • Alffenaar, J., van Ingen, J. (2017). Treatment of Mycobacterium avium-intracellulare complex: A great leap forward. Journal of Antimicrobial Chemotherapy, 72, ii1-ii2. [More Information]
  • Kuiken, N., Rings, E., Alffenaar, J., Havinga, R., Jurdzinski, A., Groen, A., Tissing, W. (2017). Tumor Necrosis Factor-Alpha Inhibitor Etanercept Does Not Alter Methotrexate-Induced Gastrointestinal Mucositis in Rats. Journal of Pediatric Gastroenterology and Nutrition, 65(2), e28-e34. [More Information]
  • Veringa, A., ter Avest, M., Span, L., van den Heuvel, E., Touw, D., Zijlstra, J., Kosterink, J., Van Der Werf, T., Alffenaar, J. (2017). Voriconazole metabolism is influenced by severe inflammation: A prospective study. Journal of Antimicrobial Chemotherapy, 72(1), 261-267. [More Information]

2016

  • Nguyen, T., Cao, T., Akkerman, O., Tiberi, S., Vu, D., Alffenaar, J. (2016). Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis. Expert Review of Clinical Pharmacology, 9(8), 1025-1037. [More Information]
  • Tiberi, S., Sotgiu, G., D�Ambrosio, L., Centis, R., Arbex, M., Arrascue, E., Alffenaar, J., Caminero, J., Gaga, M., et al (2016). Comparison of effectiveness and safety of imipenem/clavulanate-versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. European Respiratory Journal, 47(6), 1758-1766. [More Information]
  • Zuur, M., Bolhuis, M., Anthony, R., den Hertog, A., van der Laan, T., Wilffert, B., de Lange, W., van Soolingen, D., Alffenaar, J. (2016). Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis. Expert Opinion on Drug Metabolism and Toxicology, 12(5), 509-521. [More Information]
  • Cattaneo, D., Alffenaar, J., Neely, M. (2016). Drug monitoring and individual dose optimization of antimicrobial drugs: Oxazolidinones. Expert Opinion on Drug Metabolism and Toxicology, 12(5), 533-544. [More Information]
  • Tiberi, S., Payen, M., Sotgiu, G., D�Ambrosio, L., Guizado, V., Alffenaar, J., Arbex, M., Caminero, J., Centis, R., de Lorenzo, S., et al (2016). Effectiveness and safety of meropenem/ clavulanate-containing regimens in the treatment of MDR- and XDR-TB. European Respiratory Journal, 47(4), 1235-1243. [More Information]
  • Hofman, S., Segers, M., Ghimire, S., Bolhuis, M., Sturkenboom, M., van Soolingen, D., Alffenaar, J. (2016). Emerging drugs and alternative possibilities in the treatment of tuberculosis. Expert Opinion on Emerging Drugs, 21(1), 103-116. [More Information]
  • Dijkstra, J., Voerman, A., Greijdanus, B., Touw, D., Alffenaar, J. (2016). Immunoassay analysis of kanamycin in serum using the tobramycin kit. Antimicrobial Agents and Chemotherapy, 60(8), 4646-4651. [More Information]
  • Saktiawati, A., Sturkenboom, M., Stienstra, Y., Subronto, Y., Sumardi, S., Kosterink, J., Van Der Werf, T., Alffenaar, J. (2016). Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: A randomized cross-over trial. Journal of Antimicrobial Chemotherapy, 71(3), 703-710. [More Information]
  • Veringa, A., Sturkenboom, M., Dekkers, B., Koster, R., Roberts, J., Peloquin, C., Touw, D., Alffenaar, J. (2016). LC-MS/MS for Therapeutic Drug Monitoring of anti-infective drugs. Trends In Analytical Chemistry, 84, 34-40. [More Information]
  • Ventura, M., van Wanrooy, M., Span, L., Rodgers, M., van den Heuvel, E., Uges, D., Van Der Werf, T., Kosterink, J., Alffenaar, J. (2016). Longitudinal analysis of the effect of inflammation on voriconazole trough concentrations. Antimicrobial Agents and Chemotherapy, 60(5), 2727-2731. [More Information]
  • Huurneman, L., Neely, M., Veringa, A., Perez, F., Ramos-Martin, V., Tissing, W., Alffenaar, J., Hope, W. (2016). Pharmacodynamics of voriconazole in children: Further steps along the path to true individualized therapy. Antimicrobial Agents and Chemotherapy, 60(4), 2336-2342. [More Information]
  • Alsaad, N., Dijkstra, J., Akkerman, O., de Lange, W., van Soolingen, D., Kosterink, J., Van Der Werf, T., Alffenaar, J. (2016). Pharmacokinetic evaluation of sulfamethoxazole at 800 milligrams once daily in the treatment of tuberculosis. Antimicrobial Agents and Chemotherapy, 60(7), 3942-3947. [More Information]
  • Ghimire, S., van 't Boveneind-Vrubleuskaya, N., Akkerman, O., de Lange, W., van Soolingen, D., Kosterink, J., Van Der Werf, T., Wilffert, B., Touw, D., Alffenaar, J. (2016). Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB. Journal of Antimicrobial Chemotherapy, 71(10), 2691-2703. [More Information]
  • van Rijn, S., Van Altena, R., Akkerman, O., van Soolingen, D., van der Laan, T., De Lange, W., Kosterink, J., Van Der Werf, T., Alffenaar, J. (2016). Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis. European Respiratory Journal, 47(4), 1229-1234. [More Information]
  • van 't Boveneind-Vrubleuskaya, N., Daskapan, A., Kosterink, J., van Der Werf, T., van den Hof, S., Alffenaar, J. (2016). Predictors of Prolonged TB Treatment in a Dutch Outpatient Setting. PloS One, 11(11), 1-12. [More Information]
  • Srivastava, S., van Rijn, S., Wessels, A., Alffenaar, J., Gumbo, T. (2016). Susceptibility testing of antibiotics that degrade faster than the doubling time of slow-growing mycobacteria: Ertapenem sterilizing effect versus Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 60(5), 3193-3195. [More Information]
  • Dekkers, B., Bakker, M., van der Elst, K., Sturkenboom, M., Veringa, A., Span, L., Alffenaar, J. (2016). Therapeutic Drug Monitoring of Posaconazole: an Update. Current Fungal Infection Reports, 10(2), 51-61. [More Information]
  • Hoppentocht, M., Akkerman, O., Hagedoorn, P., Alffenaar, J., Van Der Werf, T., Kerstjens, H., Frijlink, H., De Boer, A. (2016). Tolerability and pharmacokinetic evaluation of inhaled dry powder tobramycin free base in non-cystic fibrosis bronchiectasis patients. PloS One, 11(3), 1-12. [More Information]
  • van Wanrooy, M., Rodgers, M., Span, L., Zijlstra, J., Uges, D., Kosterink, J., Van Der Werf, T., Alffenaar, J. (2016). Voriconazole therapeutic drug monitoring practices in intensive care. Therapeutic Drug Monitoring, 38(3), 313-318. [More Information]

2015

  • Alffenaar, J., Bolhuis, M., van Hateren, K., Sturkenboom, M., Akkerman, O., De Lange, W., Greijdanus, B., Van Der Werf, T., Touw, D. (2015). Determination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometry. Antimicrobial Agents and Chemotherapy, 59(9), 5675-5680. [More Information]
  • van der Paardt, A., Wilffert, B., Akkerman, O., De Lange, W., van Soolingen, D., Sinha, B., Van Der Werf, T., Kosterink, J., Alffenaar, J. (2015). Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis. European Respiratory Journal, 46(2), 444-455. [More Information]
  • Dijkstra, J., Van Altena, R., Akkerman, O., de Lange, W., Proost, J., Van Der Werf, T., Kosterink, J., Alffenaar, J. (2015). Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis. International Journal of Antimicrobial Agents, 46(3), 332-337. [More Information]
  • van Wanrooy, M., Proost, J., Rodgers, M., Zijlstra, J., Uges, D., Kosterink, J., Van Der Werf, T., Alffenaar, J. (2015). Limited-sampling strategies for anidulafungin in critically ill patients. Antimicrobial Agents and Chemotherapy, 59(2), 1177-1181. [More Information]
  • Sturkenboom, M., Mulder, L., de Jager, A., Van Altena, R., Aarnoutse, R., De Lange, W., Proost, J., Kosterink, J., Van Der Werf, T., Alffenaar, J. (2015). Pharmacokinetic modeling and optimal sampling strategies for therapeutic drug monitoring of rifampin in patients with tuberculosis. Antimicrobial Agents and Chemotherapy, 59(8), 4907-4913. [More Information]
  • Dijkstra, J., Alsaad, N., van Hateren, K., Greijdanus, B., Touw, D., Alffenaar, J. (2015). Quantification of co-trimoxazole in serum and plasma using MS/MS. Bioanalysis, 7(21), 2741-2749. [More Information]
  • Hofman, S., Bolhuis, M., Koster, R., Akkerman, O., van Assen, S., Stove, C., Alffenaar, J. (2015). Role of therapeutic drug monitoring in pulmonary infections: Use and potential for expanded use of dried blood spot samples. Bioanalysis, 7(4), 481-495. [More Information]
  • van der Elst, K., Brouwers, C., van den Heuvel, E., van Wanrooy, M., Uges, D., Van Der Werf, T., Kosterink, J., Span, L., Alffenaar, J. (2015). Subtherapeutic posaconazole exposure and treatment outcome in patients with invasive fungal disease. Therapeutic Drug Monitoring, 37(6), 766-771. [More Information]
  • Koster, R., Botma, R., Greijdanus, B., Uges, D., Kosterink, J., Touw, D., Alffenaar, J. (2015). The performance of five different dried blood spot cards for the analysis of six immunosuppressants. Bioanalysis, 7(10), 1225-1235. [More Information]
  • Koster, R., Alffenaar, J., Botma, R., Greijdanus, B., Uges, D., Kosterink, J., Touw, D. (2015). The relation of the number of hydrogen-bond acceptors with recoveries of immunosuppressants in DBS analysis. Bioanalysis, 7(14), 1717-1722. [More Information]
  • Sotgiu, G., Alffenaar, J., Centis, R., D�Ambrosio, L., Spanevello, A., Piana, A., Migliori, G. (2015). Therapeutic drug monitoring: How to improve drug dosage and patient safety in tuberculosis treatment. International Journal of Infectious Diseases, 32, 101-104. [More Information]
  • Koster, R., Alffenaar, J., Botma, R., Greijdanus, B., Touw, D., Uges, D., Kosterink, J. (2015). What is the right blood hematocrit preparation procedure for standards and quality control samples for dried blood spot analysis? Bioanalysis, 7(3), 345-351. [More Information]

2014

  • Koster, R., Alffenaar, J., Greijdanus, B., VanDerNagel, J., Uges, D. (2014). Application of sweat patch screening for 16 drugs and metabolites using a fast and highly selective LC-MS/MS method. Therapeutic Drug Monitoring, 36(1), 35-45. [More Information]
  • Koster, R., Alffenaar, J., Greijdanus, B., VanDerNagel, J., Uges, D. (2014). Fast and highly selective LC-MS/MS screening for THC and 16 other abused drugs and metabolites in human hair to monitor patients for drug abuse. Therapeutic Drug Monitoring, 36(2), 234-243. [More Information]
  • Lempers, V., Alffenaar, J., Touw, D., Burger, D., Uges, D., Aarnoutse, R., Bruggemann, R. (2014). Five year results of an international proficiency testing programme for measurement of antifungal drug concentrations. Journal of Antimicrobial Chemotherapy, 69(11), 2988-2994. [More Information]
  • van der Elst, K., Pereboom, M., van den Heuvel, E., Kosterink, J., Scholvinck, E., Alffenaar, J. (2014). Insufficient fluconazole exposure in pediatric cancer patients and the need for therapeutic drug monitoring in critically Ill children. Clinical Infectious Diseases, 59(11), 1527-1533. [More Information]
  • Lange, C., Abubakar, I., Alffenaar, J., Bothamley, G., Caminero, J., Carvalho, A., Chang, K., Codecasa, L., Correia, A., et al (2014). Management of patients with multidrugresistant/ extensively drug-resistant tuberculosis in Europe: A TBNET consensus statement. European Respiratory Journal, 44(1), 23-63. [More Information]
  • Dalboge, C., Nielsen, X., Dalhoff, K., Alffenaar, J., Duno, M., Buchard, A., Uges, D., Jensen, A., Jurgens, G., et al (2014). Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis. Journal of Cystic Fibrosis, 13(2), 179-185. [More Information]
  • Magis-Escurra, C., Later-Nijland, H., Alffenaar, J., Broeders, J., Burger, D., Van Crevel, R., Boeree, M., Donders, A., van Altena, R., van Der Werf, T., et al (2014). Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin. International Journal of Antimicrobial Agents, 44(3), 229-234. [More Information]
  • Alsaad, N., Wilffert, B., Van Altena, R., de Lange, W., Van Der Werf, T., Kosterink, J., Alffenaar, J. (2014). Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis. European Respiratory Journal, 43(3), 884-897. [More Information]
  • van Rijn, S., Wessels, A., Greijdanus, B., Touw, D., Alffenaar, J. (2014). Quantification and validation of ertapenem using a liquid chromatography-tandem mass spectrometry method. Antimicrobial Agents and Chemotherapy, 58(6), 3481-3484. [More Information]
  • Dijkstra, J., Sturkenboom, M., van Hateren, K., Koster, R., Greijdanus, B., Alffenaar, J. (2014). Quantification of amikacin and kanamycin in serum using a simple and validated LC-MS/MS method. Bioanalysis, 6(16), 2125-2133. [More Information]
  • Vu, D., Koster, R., Bolhuis, M., Greijdanus, B., Van Altena, R., Nguyen, D., Brouwers, J., Uges, D., Alffenaar, J. (2014). Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC-MS/MS. Talanta, 121, 9-17. [More Information]

2013

  • Bolhuis, M., Van Altena, R., van Soolingen, D., De Lange, W., Uges, D., Van Der Werf, T., Kosterink, J., Alffenaar, J. (2013). Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. European Respiratory Journal, 42(6), 1614-1621. [More Information]
  • Bolhuis, M., van Altena, R., van Hateren, K., De Lange, W., Greijdanus, B., Uges, D., Kosterink, J., Van Der Werf, T., Alffenaar, J. (2013). Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis. Antimicrobial Agents and Chemotherapy, 57(8), 3676-3680. [More Information]
  • van der Elst, K., Span, L., van Hateren, K., Vermeulen, K., Van Der Werf, T., Greijdanus, B., Kosterink, J., Uges, D., Alffenaar, J. (2013). Dried blood spot analysis suitable for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole. Antimicrobial Agents and Chemotherapy, 57(10), 4999-5004. [More Information]
  • de Lorenzo, S., Alffenaar, J., Sotgiu, G., Centis, R., D�Ambrosio, L., Tiberi, S., Bolhuis, M., Van Altena, R., Viggiani, P., Piana, A., et al (2013). Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. European Respiratory Journal, 41(6), 1386-1392. [More Information]
  • Alsaad, N., Van Altena, R., Pranger, A., van Soolingen, D., De Lange, W., Kosterink, J., Alffenaar, J. (2013). Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis. European Respiratory Journal, 42(2), 504-512. [More Information]
  • Koster, R., Alffenaar, J., Greijdanus, B., Uges, D. (2013). Fast LC-MS/MS analysis of tacrolimus, sirolimus, everolimus and cyclosporin A in dried blood spots and the influence of the hematocrit and immunosuppressant concentration on recovery. Talanta, 115, 47-54. [More Information]
  • Magis-Escurra, C., Alffenaar, J., Hoefnagels, I., Dekhuijzen, P., Boeree, M., van Ingen, J., Aarnoutse, R. (2013). Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections. International Journal of Antimicrobial Agents, 42(3), 256-261. [More Information]
  • van Wanrooy, M., Santoe, R., van der Elst, K., Wilmer, C., van Hateren, K., Wessels, A., Greijdanus, B., Alffenaar, J., Uges, D. (2013). Simultaneous Quantification of Anidulafungin and Caspofungin in Plasma by an Accurate and Simple Liquid Chromatography Tandem Mass-Spectrometric Method. Therapeutic Drug Monitoring, 35(6), 778-784. [More Information]
  • Vu, D., Koster, R., Wessels, A., Greijdanus, B., Alffenaar, J., Uges, D. (2013). Troubleshooting carry-over of LC-MS/MS method for rifampicin, clarithromycin and metabolites in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 917-918, 1-4. [More Information]

2012

  • van der Lijke, H., Alffenaar, J., Kok, W., Greijdanus, B., Uges, D. (2012). Determination of ribavirin in human serum using liquid chromatography tandem mass spectrometry. Talanta, 88, 385-390. [More Information]
  • Vu, D., Bolhuis, M., Koster, R., Greijdanus, B., De Lange, W., Van Altena, R., Brouwers, J., Uges, D., Alffenaar, J. (2012). Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Antimicrobial Agents and Chemotherapy, 56(11), 5758-5763. [More Information]
  • Sotgiu, G., Centis, R., D�Ambrosio, L., Alffenaar, J., Anger, H., Caminero, J., Castiglia, P., de Lorenzo, S., Ferrara, G., Koh, W., et al (2012). Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: Systematic review and meta-analysis. European Respiratory Journal, 40(6), 1430-1442. [More Information]
  • van der Elst, K., Bruggemann, R., Rodgers, M., Alffenaar, J. (2012). Plasma concentrations of caspofungin at two different dosage regimens in a patient with hepatic dysfunction. Transplant Infectious Disease, 14(4), 440-443. [More Information]

For support on your academic profile contact .